Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.41 |
| ▸ | WIZ | O95785 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21897714 | 0.88 | POLB (0.47) | CRBNDDB1CSNK1A1 | |
| SCHEMBL24294674 | 0.85 | CRBN (0.45) | CRBNDDB1CSNK1A1 | |
| SCHEMBL20323937 | 0.85 | CRBN (0.45) | CRBNDDB1CSNK1A1 | |
| SCHEMBL25771919 | 0.83 | CRBN (0.46) | CRBNDDB1 | |
| SCHEMBL24870630 | 0.83 | MAOA (0.40) | CRBNDDB1KDM4EKMT2AWIZ | |
| SCHEMBL24654316 | 0.83 | ADRA2A (0.40) | CRBNDDB1WIZ | |
| SCHEMBL21982837 | 0.83 | ADRA2A (0.40) | CRBNDDB1WIZ | |
| SCHEMBL29307105 | 0.83 | CRBN (0.43) | CRBNDDB1 | |
| SCHEMBL22512216 | 0.82 | CRBN (0.57) | CRBNDDB1 | |
| SCHEMBL21760038 | 0.82 | CRBN (0.44) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885DDB1 480/4885KDM4E 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.